Skip to main content
Log in

Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy

  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

With recent advances in pancreatic imaging and surgical techniques, a distinct subset of pancreatic tumors is emerging that blurs the distinction between resectable and locally advanced disease: tumors of “borderline resectability.” In our practice, patients with borderline-resectable pancreatic cancer include those whose tumors exhibit encasement of a short segment of the hepatic artery, without evidence of tumor extension to the celiac axis, that is amenable to resection and reconstruction; tumor abutment of the superior mesenteric artery involving <180° of the circumference of the artery; or short-segment occlusion of the superior mesenteric vein, portal vein, or their confluence with a suitable option available for vascular reconstruction because the veins are normal above and below the area of tumor involvement. With currently available surgical techniques, patients with borderline-resectable pancreatic head cancer are at high risk for a margin-positive resection. Therefore, our approach to these patients is to use preoperative systemic therapy and local-regional chemoradiation to maximize the potential for an R0 resection and to avoid R2 resections. In our experience, patients with favorable responses to preoperative therapy (radiographical evidence of tumor regression and improvement in serum tumor marker levels) are the subset of patients who have the best chance for an R0 resection and a favorable long-term outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig 1
Fig 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Wolff RA, Abbruzzese JL, Evans DB. Neoplasms of the exocrine pancreas. In: Bast RC Jr, Kufe DW, Pollock RE, et al., eds. Cancer Medicine. 6th ed. Hamilton, Ontario, Canada: American Cancer Society + BC Decker Inc, 2003: 1585–614

  2. Li D, Xie K, Wolff RA, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049–57

    Article  PubMed  CAS  Google Scholar 

  3. Millikan KW, Deziel DJ, Silverstein JC, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 1999; 65:618–23; discussion 623–4

    PubMed  CAS  Google Scholar 

  4. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4:567–79

    Article  PubMed  CAS  Google Scholar 

  5. Benassai G, Mastrorilli M, Quarto G, Cappiello A, Giani U, Mosella G. Survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Chir Ital 2000; 52:263–70

    PubMed  CAS  Google Scholar 

  6. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234:758–68

    Article  PubMed  CAS  Google Scholar 

  7. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003; 27:324–9

    Article  PubMed  Google Scholar 

  8. Takai S, Satoi S, Toyokawa H, et al. Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas 2003; 26:243–9

    Article  PubMed  CAS  Google Scholar 

  9. Kuhlmann KF, de Castro SM, Wesseling JG, et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004; 40:549–58

    Article  PubMed  CAS  Google Scholar 

  10. Saldinger PF, Reilly M, Reynolds K, et al. Is CT angiography sufficient for prediction of resectability of periampullary neoplasms? J Gastrointest Surg 2000; 4:233–7; discussion 238–9

    Article  PubMed  CAS  Google Scholar 

  11. Tamm E, Charnsangavej C, Szklaruk J. Advanced 3-D imaging for the evaluation of pancreatic cancer with multidetector CT. Int J Gastrointest Cancer 2001; 30:65–71

    Article  PubMed  CAS  Google Scholar 

  12. Faria SC, Tamm EP, Loyer EM, Szklaruk J, Choi H, Charnsangavej C. Diagnosis and staging of pancreatic tumors. Semin Roentgenol 2004; 39:397–411

    Article  PubMed  Google Scholar 

  13. Kulig J, Popiela T, Zajac A, Klek S, Kolodziejczyk P. The value of imaging techniques in the staging of pancreatic cancer. Surg Endosc 2005; 19:361–5

    Article  PubMed  CAS  Google Scholar 

  14. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004; 8:935–50

    Article  PubMed  Google Scholar 

  15. Pisters PW, Lee JE, Vauthey JN, Charnsangavej C, Evans DB. Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001; 88:325–37

    Article  PubMed  CAS  Google Scholar 

  16. Schmidt J, Fraunhofer S, Fleisch M, Zirngibl H. Is peritoneal cytology a predictor of unresectability in pancreatic carcinoma? Hepatogastroenterology 2004; 51:1827–31

    PubMed  Google Scholar 

  17. Zhao ZW, He JY, Tan G, Wang HJ, Li KJ. Laparoscopy and laparoscopic ultrasonography in judging the resectability of pancreatic head cancer. Hepatobiliary Pancreat Dis Int 2003; 2:609–11

    PubMed  Google Scholar 

  18. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002

    Google Scholar 

  19. National Comprehensive Cancer Network (NCCN) Practice Guidelines for Pancreatic Cancer. Available at: http://www.nccn.org. 2004 (last accessed 12-2-05)

  20. Loyer EM, David CL, Dubrow RA, Evans DB, Charnsangavej C. Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT. Abdom Imaging 1996; 21:202–6

    Article  PubMed  CAS  Google Scholar 

  21. Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 1997; 168:1439–43

    PubMed  CAS  Google Scholar 

  22. Valls C, Andia E, Sanchez A, et al. Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol 2002; 178:821–6

    PubMed  Google Scholar 

  23. White RR, Tyler DS. Neoadjuvant therapy for pancreatic cancer: the Duke experience. Surg Oncol Clin North Am 2004; 13:675–84

    Article  Google Scholar 

  24. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997; 15:928–37

    PubMed  CAS  Google Scholar 

  25. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001; 8:123–32

    PubMed  CAS  Google Scholar 

  26. Pisters PW, Wolff RA, Janjan NA, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 2002; 20:2537–44

    Article  PubMed  CAS  Google Scholar 

  27. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 6:1936–48

    PubMed  CAS  Google Scholar 

  28. Moore MJ Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] (abstract 1). American Society of Clinical Oncology, Orlando, Florida, May 13–17, 2005.

  29. Kortmansky JS, O’Reilly EM, Minsky BD, et al. A phase I trial of erlotinib, gemcitabine and radiation for patients with locally advanced, unresectable pancreatic cancer (abstract 133). American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, Hollywood, Florida, January 27–29, 2005

  30. Iannitti D, Dipetrillo T, Akerman P, et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. J Clin Oncol 2005; 28:570–5

    Article  CAS  Google Scholar 

  31. Crane CH, Ellis LM, Abbruzzese JL, et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006;24:1145–51

    Article  PubMed  CAS  Google Scholar 

  32. Chen VK, Arguedas MR, Kilgore ML, Eloubeidi MA. A cost-minimization analysis of alternative strategies in diagnosing pancreatic cancer. Am J Gastroenterol 2004; 99:2223–34

    Article  PubMed  Google Scholar 

  33. Levy MJ, Wiersema MJ. Pancreatic neoplasms. Gastrointest Endosc Clin North Am 2005; 15:117–42

    Article  Google Scholar 

  34. Eloubeidi MA, Gress FG, Savides TJ, et al. Acute pancreatitis after EUS-guided FNA of solid pancreatic masses: a pooled analysis from EUS centers in the United States. Gastrointest Endosc 2004; 60:385–9

    Article  PubMed  Google Scholar 

  35. Raut CP, Grau AM, Staerkel GA, et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg 2003; 7:118–26; discussion 127–8

    Article  PubMed  Google Scholar 

  36. Pisters PW, Hudec WA, Lee JE, et al. Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol 2000; 18:860–7

    PubMed  CAS  Google Scholar 

  37. Mullen JT, Lee JH, Gomez HF, et al. Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg 2005; 9:1094–105

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Supported by The Lockton Fund for Pancreatic Cancer Research at The University of Texas M. D. Anderson Cancer Center.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gauri R. Varadhachary MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Varadhachary, G.R., Tamm, E.P., Abbruzzese, J.L. et al. Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy. Ann Surg Oncol 13, 1035–1046 (2006). https://doi.org/10.1245/ASO.2006.08.011

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2006.08.011

Keywords

Navigation